A5064343766- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Drug Transport and Resistance Mechanisms
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Microtubule and mitosis dynamics
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatitis Pathology and Treatment
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
Sylvester Comprehensive Cancer Center
2019-2024
University of Miami
2017-2024
Medical University of South Carolina
2021-2024
MUSC Hollings Cancer Center
2021-2024
Washington University in St. Louis
2014-2023
Weatherford College
2023
Algarve Biomedical Center
2018
Universidade do Porto
2018
University of Algarve
2018
Alvin J. Siteman Cancer Center
2016-2017
Gastric cancer is the fifth most frequently diagnosed and third leading cause of death from in world. Several advances have been made staging procedures, imaging techniques, treatment approaches. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Cancer provide an evidence- consensus-based approach management patients with gastric cancer. This manuscript discusses recommendations outlined staging, assessment HER2 overexpression, systemic therapy locally advanced or...
The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations a multidisciplinary approach the management of patients with gastric cancer. For resectable locoregional cancer, guidelines recommend gastrectomy D1+ or modified D2 lymph node dissection (performed by experienced surgeons high-volume centers). Postoperative chemoradiation is preferred option after complete resection T3-T4 tumors node-positive T1-T2 tumors. chemotherapy...
Esophageal cancer is the sixth most common cause of deaths worldwide. Adenocarcinoma more in North America and Western European countries, originating mostly lower third esophagus, which often involves esophagogastric junction (EGJ). Recent randomized trials have shown that addition preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival patients with resectable cancer. Targeted therapies trastuzumab ramucirumab produced encouraging results...
<h3>Importance</h3> Effective treatment options are limited for patients with advanced, metastatic esophageal cancer progressing after 2 or more lines of systemic therapy. <h3>Objective</h3> To evaluate the efficacy and safety pembrolizumab squamous cell carcinoma (ESCC) adenocarcinoma esophagus gastroesophageal junction that progressed <h3>Design, Setting, Participants</h3> This phase 2, open-label, interventional, single-arm study, KEYNOTE-180, enrolled 121 from January 12, 2016, to March...
Overview Upper gastrointestinal tract cancers originating in the esophagus, esophagogastric junction (EGJ), and stomach constitute a major health problem around world. An estimated 37,640 new cases of 25,070 deaths from upper occurred United States 2010.1 A dramatic shift location tumors has States.2,3 Changes hisNCCN
KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor wild-type (WT). We aim to characterize the molecular profiles WT PDAC uncover new pathogenic drivers and offer targeted treatments.
5533 Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report safety and activity of avelumab patients (pts) with recurrent/refractory ovarian cancer (OC; NCT01772004). Methods: Pts advanced OC unselected for PD-L1 expression received 10 mg/kg IV Q2W until progression, unacceptable toxicity, or withdrawal. Tumors were assessed every 6 wks (RECIST 1.1). Unconfirmed objective response rate (ORR), progression-free survival...
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.The purpose of this study examine the tolerance effectiveness as practiced outside confines clinical trial document any dose modifications used by practicing oncologists.Data on patients all stages pancreatic adenocarcinoma treated at three institutions analyzed for efficacy, tolerance, use modifications.Total 61 included review. Median age 58...
5509 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of immune response against multiple cancers. Avelumab (proposed INN) (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently being investigated clinical trials. Here we present results from cohort patients (pts) with recurrent or refractory ovarian cancer an ongoing phase Ib study (NCT01772004). Methods: Pts ECOG PS 0-1 received avelumab at 10 mg/kg Q2W....
Colorectal cancer (CRC) remains one of the major causes death worldwide, despite steady improvement in early detection and overall survival over past decade. Current treatment paradigms, with chemotherapy biologics, appear to have reached their maximum benefit. Immunotherapy, especially checkpoint inhibitors, has shown considerable clinical benefit various cancers, including mismatch-repair-deficient CRC. This led planning initiation several trials evaluating novel immunotherapy agents—as...
Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has tolerable safety profile.We conducted multicenter, open-label, phase I study with dose escalation and expansion phases. In escalation, patients refractory solid tumors were treated at five escalating levels of defactinib gemcitabine to identify recommended II (RP2D). phase, metastatic PDAC who...
Purpose Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the vascular endothelial growth factor and multiple other receptors. We assessed safety efficacy sunitinib in patients with metastatic colorectal cancer after failure standard therapy. Patients Methods Eighty-four were enrolled onto this two-stage phase II trial stratified by whether they had received prior bevacizumab (n = 43) or not 41). Treatment comprised 50 mg orally daily for 4 weeks, followed 2 weeks off...
Abstract Organic anion transporting polypeptide 1B3 (OATP1B3, SLCO1B3) is normally expressed in hepatocytes. In this study, we showed frequent overexpression of OATP1B3 colorectal adenocarcinomas. Quantitative reverse transcription-PCR analysis 17 colon tumors indicated tumoral by ∼100-fold, compared with 20 normal samples (P &lt; 0.0001). Using immunohistochemistry on a tissue microarray containing 93 evaluable tumor specimens, detected immunostaining 75 adenocarcinomas (81%) and no...
Mutations in TP53 lead to a defective G1 checkpoint and the dependence on kinase 1 (Chk1) for G2 or S phase arrest response DNA damage. In preclinical studies, Chk1 inhibition resulted enhanced cytotoxicity of several chemotherapeutic agents. The high frequency mutations triple negative breast cancer (TNBC: estrogen receptor, progesterone HER2) make an attractive therapeutic target. UCN-01, non-selective inhibitor, combined with irinotecan demonstrated activity advanced TNBC our Phase I...
Abstract Secondary bile acids (BA) such as deoxycholic acid (DCA) promote the development of several gastrointestinal malignancies, but how they mediate this effect is unclear. In study, we offer evidence a mechanism involving ectodomain shedding EGFR ligands amphiregulin (AREG) and TGF-α, which rely upon cell surface protease TACE/ADAM-17. Specifically, show that AREG participates in DCA-induced STAT3 signaling, cell-cycle progression, tumorigenicity human colorectal cancer pancreatic...
Background Retrospective studies indicate associations between TSER (thymidylate synthase enhancer region) genotypes and clinical outcomes in patients receiving 5-FU based chemotherapy, but well-controlled prospective validation has been lacking. Methods In this phase II study (NCT00515216 registered through ClinicalTrials.gov, http://clinicaltrials.gov/show/NCT00515216), with “good risk” (at least one TSER*2 allele) were treated FOLFOX chemotherapy to determine whether patient selection can...
Abstract Purpose: Mammaglobin-A (MAM-A) is overexpressed in 40% to 80% of primary breast cancers. We initiated a phase I clinical trial MAM-A DNA vaccine evaluate its safety and biologic efficacy. Experimental Design: Patients with cancer stable metastatic disease were eligible for enrollment. Safety was monitored laboratory assessments. The CD8 T-cell response measured by ELISPOT, flow cytometry, cytotoxicity assays. Progression-free survival (PFS) described using the Kaplan–Meier product...